Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbareschi

Showing results (281-290 of 357) with videos related to

Pageof 36
Sort By:
Cell Death & Disease|April 11, 2023
ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1/NF-κB axisErna Marija Meškytė, Laura Pezzè, Laura Bartolomei, et al.
Genes, Chromosomes & Cancer|May 26, 2016
Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysisClaudio Luchini, Nicola Veronese, Shinichi Yachida, et al.
International Journal of Health Policy and Management|November 17, 2020
Assistive Technology Use and Provision During COVID-19: Results From a Rapid Global SurveyEmma M Smith, Maria Luisa Toro Hernandez, Ikenna D Ebuenyi, et al.
Virchows Archiv : an International Journal of Pathology|June 30, 2012
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapyMattia Barbareschi, Lucia Veronica Cuorvo, Salvatore Girlando, et al.
International Journal of Cancer|June 22, 2000
p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-upM Barbareschi, H van Tinteren, F A Mauri, et al.
International Journal of Cancer|January 22, 2002
Prognostic value of thymidine phosphorylase expression in breast carcinomaQifeng Yang, Mattia Barbareschi, Ichiro Mori, et al.
International Journal of Cancer|February 14, 1998
Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancerA Marchetti, C Doglioni, M Barbareschi, et al.
Pathologica|May 22, 2023
POLE exonuclease domain mutations in endometrial carcinoma: a case reportMaria Paola Pasciuto, Lara Felicioni, Claudia Zampacorta, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2011
Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimensGiuseppe Pelosi, Giulio Rossi, Fabrizio Bianchi, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 5, 2011
Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved systemChiara Cantaloni, Eugenia Tonini R, Claudio Eccher, et al.
Pageof 36

Showing results (281-290 of 357) with videos related to

Sort By:
Pageof 36
Cell Death & Disease|April 11, 2023
ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1/NF-κB axisErna Marija Meškytė, Laura Pezzè, Laura Bartolomei, et al.
Genes, Chromosomes & Cancer|May 26, 2016
Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysisClaudio Luchini, Nicola Veronese, Shinichi Yachida, et al.
International Journal of Health Policy and Management|November 17, 2020
Assistive Technology Use and Provision During COVID-19: Results From a Rapid Global SurveyEmma M Smith, Maria Luisa Toro Hernandez, Ikenna D Ebuenyi, et al.
Virchows Archiv : an International Journal of Pathology|June 30, 2012
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapyMattia Barbareschi, Lucia Veronica Cuorvo, Salvatore Girlando, et al.
International Journal of Cancer|June 22, 2000
p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-upM Barbareschi, H van Tinteren, F A Mauri, et al.
International Journal of Cancer|January 22, 2002
Prognostic value of thymidine phosphorylase expression in breast carcinomaQifeng Yang, Mattia Barbareschi, Ichiro Mori, et al.
International Journal of Cancer|February 14, 1998
Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancerA Marchetti, C Doglioni, M Barbareschi, et al.
Pathologica|May 22, 2023
POLE exonuclease domain mutations in endometrial carcinoma: a case reportMaria Paola Pasciuto, Lara Felicioni, Claudia Zampacorta, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 23, 2011
Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimensGiuseppe Pelosi, Giulio Rossi, Fabrizio Bianchi, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 5, 2011
Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved systemChiara Cantaloni, Eugenia Tonini R, Claudio Eccher, et al.
Pageof 36